Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder (Q34603527)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

0 references

0 references

author name string

D Elie

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

M Poirier

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jm Chianetta

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

M Durand

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ca Grégoire

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

S Grignon

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

22 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Journal of Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1037-1044

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Factors associated with antipsychotic dosing in psychiatric inpatients: a prospective study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Inpatient antipsychotic drug use in 1998, 1993, and 1989.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Comparative psychometric properties of the BACS and RBANS in patients with schizophrenia and schizoaffective disorder.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Dosing of Second-Generation Antipsychotic Medication in a State Hospital System

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Dose response and dose equivalence of antipsychotics

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Clozapine alone versus clozapine and risperidone with refractory schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Antipsychotic medication and cognitive function in schizophrenia.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

The relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to functional capacity and real-world functional outcome

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Pharmacokinetic-pharmacodynamic analysis of antipsychotics-induced extrapyramidal symptoms based on receptor occupancy theory incorporating endogenous dopamine release.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

The National Adult Reading Test as a measure of premorbid IQ in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

High dose antipsychotic use in schizophrenia: findings of the REAP (research on east Asia psychotropic prescriptions) study.

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Focus on antipsychotic polypharmacy: evidence-based prescribing or prescribing-based evidence?

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Exploring cognitive complaints in schizophrenia: the subjective scale to investigate cognition in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Age at onset and cognitive functioning in schizophrenia

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis

1 reference

https://api.crossref.org/works/10.1177%2F0269881108100777

21 January 2018

Identifiers

10.1177/0269881108100777

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34603527&oldid=1556718232"